Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antitumor agents containing the anthracene nucleus.

T P Wunz, R T Dorr, D S Alberts

    Journal of Medicinal Chemistry
    |August 1, 1987
    PubMed
    Summary

    Researchers synthesized novel anthracene compounds, finding two potent against human tumor cell lines in vitro. Fresh tumor and leukemia cell assays better predicted in vivo efficacy than established cell lines, suggesting a distinct mechanism from bisantrene.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Fyn is a redox sensor involved in solar ultraviolet light-induced signal transduction in skin carcinogenesis.

    Oncogene·2015
    Same author

    Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    Promising agents for chemoprevention of skin cancer.

    Current oncology (Toronto, Ont.)·2012
    Same author

    Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study.

    Cancer causes & control : CCC·2012
    Same author

    Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.

    International journal of immunopathology and pharmacology·2011
    Same author

    Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

    Gynecologic oncology·2007

    Area of Science:

    • Medicinal Chemistry
    • Cancer Research
    • Pharmacology

    Background:

    • Bisantrene is an anthracene-based anticancer agent.
    • Development of novel anticancer agents with improved efficacy and distinct mechanisms is crucial.

    Purpose of the Study:

    • To synthesize and evaluate new bisantrene analogs for anticancer activity.
    • To identify compounds with potent in vitro and in vivo anticancer effects.
    • To investigate the mechanism of action and predictive value of different assays.

    Main Methods:

    • Synthesis of 21 new bisantrene-related compounds.
    • In vitro testing using clonogenic assays against human tumor cell lines, fresh human tumors, and P-388 leukemia.
    • In vivo evaluation in mouse tumor models.

    Related Experiment Videos

  • Toxicological studies including neurotoxicity and skin ulceration assessment.

    • Main Results:

    • Two compounds, N,N'-bis[2-(dimethylamino)ethyl]-9,10-anthracenebis(methylamine) (6) and N,N'-bis(1-ethyl-3-piperidinyl)-9,10-anthracenebis(methylamine) (19), showed high in vitro activity against human tumor cell lines.
    • Compounds 6 and 19 exhibited limited activity in fresh human tumors, P-388 leukemia cells, and mouse tumor models.
    • In vitro testing using fresh human tumors and P-388 leukemia cells proved to be better predictors of in vivo activity than established cell lines.
    • Compound 6 did not inhibit macromolecular synthesis or promote DNA single-strand breakage at cytotoxic concentrations, unlike bisantrene.
    • Acute neurotoxicity and skin ulcers were observed toxicological effects.

    Conclusions:

    • Novel anthracene compounds with saturated side chains and two basic nitrogens demonstrate significant in vitro anticancer activity.
    • Fresh tumor and leukemia cell assays are more predictive of in vivo efficacy for these compounds than standard cell lines.
    • The tested compounds exhibit a distinct mechanism of action compared to bisantrene.
    • Further investigation into these compounds may lead to new therapeutic strategies, despite observed toxicities.